Switching to quetiapine fumarate monotherapy for treatment-resistant schizophrenia: A report of five cases

Authors

  • Tomás Sánchez-Araña Moreno Mental Health Clinical Management Unit of the Hospital Universitario de Puerto Real (Cádiz) Servicio Andaluz de Salud
  • Sergio Ruiz-Doblado Mental Health Clinical Management Unit of the Hospital Nuestra Señora de la Merced Osuna (Sevilla) Servicio Andaluz de Salud
  • Julián Elorza-Guisasola Mental Health Clinical Management Unit of the Hospital Universitario de Puerto Real (Cádiz) Servicio Andaluz de Salud
  • Eulalio Valmisa-Gómez de Lara Mental Health Clinical Management Unit of the Hospital Universitario de Puerto Real (Cádiz) Servicio Andaluz de Salud

Keywords:

Schizophrenia, Treatment-resistant, Antipsychotics, Quetiapine fumarate

Abstract

We assessed the efficacy and tolerance of switching to monotherapy with quetiapine fumarate (QF) in treatmentresistant schizophrenia with other antipsychotics, including atypical ones. QF treatment was maintained for 8 weeks. The PANSS scores improved at least 40% over this period. QF was well tolerated without the presence of serious adverse effects. Switching to QF in these patients may therefore be considered as optimal in response and tolerance.

Downloads

Published

2011-09-01

How to Cite

Sánchez-Araña Moreno, Tomás, et al. “Switching to Quetiapine Fumarate Monotherapy for Treatment-Resistant Schizophrenia: A Report of Five Cases”. Actas Españolas De Psiquiatría, vol. 39, no. 5, Sept. 2011, pp. 336-8, https://actaspsiquiatria.es/index.php/actas/article/view/796.

Issue

Vol. 39 No. 5 (2011)

Section

Clinical Note